<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00912171</url>
  </required_header>
  <id_info>
    <org_study_id>118/2007/O/Sper</org_study_id>
    <nct_id>NCT00912171</nct_id>
  </id_info>
  <brief_title>Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome in Children</brief_title>
  <acronym>SB-OSAS</acronym>
  <official_title>Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome (OSAS) in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bologna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the project is to evaluate whether therapy with leukotriene may be a valid
      therapeutic approach in children with adenotonsillar hypertrophy and with mild and moderate
      obstructive sleep apnea syndrome (OSAS) and to evaluate whether leukotriene is less, equally
      or more efficient than nasal steroid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the project is to evaluate whether leukotriene is less, equally or more efficient
      than nasal steroid in children with adenotonsillar hypertrophy and with mild and moderate
      OSAS checking if leukotriene administrated for 24 weeks improves overnight oximetry,
      polysomnography and checking if leukotriene as anti-inflammatory of upper airway really
      reduces the tonsils and adenoids dimensions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nocturnal polysomnography in the first visit compared with Nocturnal polysomnography in the last visit in patient with Montelukast treatment:</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the clinical upper airway patency during the night in the patients with history of allergic rhinitis compared with the patients without history of allergic rhinitis first and after the treatment for OSAS</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Obstructive Sleep Apnea Syndrome</condition>
  <arm_group>
    <arm_group_label>Nasal steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-leukotrienes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal steroid + anti-leukotrienes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide (Aircort 50 nasal spray)</intervention_name>
    <description>50 mcg per nostril once daily for cycles of 21 days with a break of 7 days for 6 months</description>
    <arm_group_label>Nasal steroid</arm_group_label>
    <arm_group_label>Nasal steroid + anti-leukotrienes</arm_group_label>
    <other_name>Aircort 50 nasal spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast (Singulair)</intervention_name>
    <description>Daily administration in 4 mg chewable tablet for children younger than 6 years or in 5 mg tablet for children 6 years and older</description>
    <arm_group_label>Anti-leukotrienes</arm_group_label>
    <arm_group_label>Nasal steroid + anti-leukotrienes</arm_group_label>
    <other_name>Singulair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of mild (RDI 3- &lt;5) or moderate obstructive apneas (RDI 5-8) by overnight
             polysomnographic evaluation with 4 channels EEG

          -  Adenotonsillar hypertrophy Friedman score's II-III-IVÂ°

        Exclusion Criteria:

          -  Neuromuscular, gastrointestinal, neurological diseases and syndromes of malformations

          -  Use of leukotrienes and/or nasal and oral steroids in the 4 weeks preceding the
             initial sleep study

          -  Acute upper respiratory tract infections

          -  Adenotonsillectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo Bernardi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bologna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department if Pediatrics, Hospital S. Orsola-Malpighi , University of Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Gozal D, Crabtree VM, Sans Capdevila O, Witcher LA, Kheirandish-Gozal L. C-reactive protein, obstructive sleep apnea, and cognitive dysfunction in school-aged children. Am J Respir Crit Care Med. 2007 Jul 15;176(2):188-93. Epub 2007 Mar 30.</citation>
    <PMID>17400731</PMID>
  </reference>
  <reference>
    <citation>Goldbart AD, Krishna J, Li RC, Serpero LD, Gozal D. Inflammatory mediators in exhaled breath condensate of children with obstructive sleep apnea syndrome. Chest. 2006 Jul;130(1):143-8.</citation>
    <PMID>16840394</PMID>
  </reference>
  <reference>
    <citation>Gozal D, Kheirandish-Gozal L. Sleep apnea in children--treatment considerations. Paediatr Respir Rev. 2006;7 Suppl 1:S58-61. Epub 2006 Jun 5. Review.</citation>
    <PMID>16798597</PMID>
  </reference>
  <reference>
    <citation>Kheirandish L, Goldbart AD, Gozal D. Intranasal steroids and oral leukotriene modifier therapy in residual sleep-disordered breathing after tonsillectomy and adenoidectomy in children. Pediatrics. 2006 Jan;117(1):e61-6.</citation>
    <PMID>16396849</PMID>
  </reference>
  <reference>
    <citation>Goldbart AD, Goldman JL, Veling MC, Gozal D. Leukotriene modifier therapy for mild sleep-disordered breathing in children. Am J Respir Crit Care Med. 2005 Aug 1;172(3):364-70. Epub 2005 May 5.</citation>
    <PMID>15879419</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2009</study_first_submitted>
  <study_first_submitted_qc>June 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <last_update_submitted>February 14, 2013</last_update_submitted>
  <last_update_submitted_qc>February 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bologna</investigator_affiliation>
    <investigator_full_name>Filippo Bernardi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>obstructive sleep apnea syndrome</keyword>
  <keyword>snoring</keyword>
  <keyword>adenotonsillar hypertrophy</keyword>
  <keyword>polysomnography</keyword>
  <keyword>intranasal steroids</keyword>
  <keyword>Anti-leukotrienes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Leukotriene Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

